AlveoGene Launches to Develop Unique Inhaled Gene Therapies for Rare Respiratory Disorders
AlveoGene has been created by OSE, Harrington and OCC in partnership with six leading scientists from the world-renowned UK Respiratory Gene Therapy Consortium (GTC).
- AlveoGene has been created by OSE, Harrington and OCC in partnership with six leading scientists from the world-renowned UK Respiratory Gene Therapy Consortium (GTC).
- AlveoGene will also evaluate the potential of the InGenuiTy™ platform alongside other technologies to create a pipeline of novel inhaled gene therapies targeting other rare respiratory disease opportunities, such as lung surfactant deficiencies and idiopathic pulmonary fibrosis.
- This will enable AlveoGene to rapidly advance our first candidate – AVG-001 a unique, inhaled gene therapy for AATD – towards clinical development.
- AlveoGene is the culmination of a successful collaboration between leading researchers from top-ranked UK universities, via GTC, and we believe the company has the potential to become a leader in respiratory gene therapy.